{
  "abstract": "Since the publication of the landmark ATOM2 (atropine for the treatment of myopia)1 and low-concentration atropine for myopia progression (LAMP) findings,2 low-concentration atropine eyedrops have been a preferred treatment method for myopia control. The ATOM series further inspired several other randomised controlled trials (figure 1), most of which showed that 0.01% atropine eyedrops have some myopia control effect. However, the efficacy of 0.01% atropine varied widely between studies, and this variation is not well explained by baseline spherical equivalent or age (figure 1). The LAMP study2 further reported slightly higher myopia control efficacy with 0.05% concentration, while maintaining a low risk profile. The crossover MOSAIC (myopia outcome study of atropine in children)3 similarly found that, in Irish children, a 0.05% concentration was more effective than a 0.01%, although with smaller effects than those observed in LAMP (figure 1).",
  "authors": [
    {
      "affiliations": [
        "Genetics and Epidemiology, Lions Eye Institute, Nedlands, Western Australia, Australia",
        "Centre for Ophthalmology and Visual Sciences, University of Western Australia, Western Australia, Australia",
        "School of Optometry and Vision Science, UNSW, Sydney, New South Wales, Australia"
      ],
      "name": "Samantha Sze-Yee Lee"
    }
  ],
  "title": "Myopia: personalise the prevention and control at commencement",
  "uid": "0bcade93-bb02-5ab1-91af-e9ca2a140478"
}